China Pharma (CPHI) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 08, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Entity Central Index Key	0001106644
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity File Number	001-34471
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity Common Stock, Shares Outstanding		43,579,557

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 761,606	$ 1,186,587
Restricted cash	489,208	1,273,940
Banker's acceptances		20,579
Trade accounts receivable, less allowance for doubtful accounts of $17,360,530 and $17,815,075, respectively	693,353	916,931
Other receivables, less allowance for doubtful accounts of $46,644 and $34,884, respectively	189,524	170,098
Advances to suppliers	2,933	47
Inventory	3,973,373	5,054,975
Prepaid expenses	129,248	123,759
Total Current Assets	6,239,245	8,746,916
Advances for purchases of intangible assets	16,595,462	17,069,587
Property, plant and equipment, net	16,697,256	19,294,379
Operating lease right of use asset	157,177
Intangible assets, net	211,491	266,443
TOTAL ASSETS	39,900,631	45,377,325
Current Liabilities:
Trade accounts payable	1,158,067	1,060,934
Accrued expenses	140,753	310,804
Other payables	3,035,431	3,065,508
Advances from customers	498,768	525,647
Other payables - related parties	2,076,972	1,633,263
Operating lease liability, current portion	88,996
Current portion of construction loan facility	2,120,771	2,181,360
Bankers' acceptance notes payable	489,208	1,273,940
Total Current Liabilities	9,608,966	10,051,456
Non-current Liabilities:
Construction loan facility	2,120,771	4,362,720
Operating lease liability, net of current portion	70,952
Deferred tax liability	743,143	764,374
Total Liabilities	12,543,832	15,178,550
Commitments and Contingencies (Note 13)
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580
Additional paid-in capital	23,590,204	23,590,204
Accumulated deficit	(7,227,146)	(5,270,358)
Accumulated other comprehensive income	10,950,161	11,835,349
Total Stockholders' Equity	27,356,799	30,198,775
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 39,900,631	$ 45,377,325

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts	$ 17,360,530	$ 17,815,075
Other receivables, less allowance for doubtful accounts	$ 46,644	$ 34,884
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	43,579,557	43,579,557
Common stock, shares outstanding	43,579,557	43,579,557

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenue	$ 2,376,844	$ 2,298,472	$ 7,875,525	$ 9,087,867
Cost of revenue	2,004,085	1,785,927	6,682,688	6,942,141
Gross profit	372,759	512,545	1,192,837	2,145,726
Operating expenses:
Selling expenses	613,110	925,654	1,597,667	2,320,204
General and administrative expenses	333,833	327,161	1,097,200	1,172,314
Research and development expenses	39,716	62,059	175,642	107,946
Bad debt expense	31,304	1,129,105	54,708	1,481,786
Total operating expenses	1,017,963	2,443,979	2,925,217	5,082,250
Loss from operations	(645,204)	(1,931,434)	(1,732,380)	(2,936,524)
Other income (expense):
Interest income	11,840	16,113	27,216	27,931
Interest expense	(67,590)	(101,683)	(251,624)	(361,365)
Net other expense	(55,750)	(85,570)	(224,408)	(333,434)
Loss before income taxes	(700,954)	(2,017,004)	(1,956,788)	(3,269,958)
Income tax expense		160,485		111,910
Net loss	(700,954)	(1,856,519)	(1,956,788)	(3,158,048)
Other comprehensive income - foreign currency translation adjustment	(909,889)	(1,535,424)	(885,188)	(2,280,131)
Comprehensive loss	$ (1,610,843)	$ (3,391,943)	$ (2,841,976)	$ (5,438,179)
Loss per share:
Basic and diluted	$ (0.02)	$ (0.04)	$ (0.04)	$ (0.07)
Weighted average shares outstanding	43,579,557	43,579,557	43,579,557	43,579,557

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit/Retained Earnings	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2017	$ 43,580	$ 23,590,204	$ 5,479,809	$ 13,957,709	$ 43,071,302
Balance, shares at Dec. 31, 2017	43,579,557
Net loss			(293,480)		(293,480)
Foreign currency translation adjustment				1,674,076	1,674,076
Balance at Mar. 31, 2018	$ 43,580	23,590,204	5,186,329	15,631,785	44,451,898
Balance, shares at Mar. 31, 2018	43,579,557
Net loss			(1,008,049)		(1,008,049)
Foreign currency translation adjustment				(2,418,783)	(2,418,783)
Balance at Jun. 30, 2018	$ 43,580	23,590,204	4,178,280	13,213,002	41,025,066
Balance, shares at Jun. 30, 2018	43,579,557
Net loss			(1,856,519)		(1,856,519)
Foreign currency translation adjustment				(1,535,424)	(1,535,424)
Balance at Sep. 30, 2018	$ 43,580	23,590,204	2,321,761	11,677,578	37,633,123
Balance, shares at Sep. 30, 2018	43,579,557
Balance at Dec. 31, 2018	$ 43,580	23,590,204	(5,270,358)	11,835,349	30,198,775
Balance, shares at Dec. 31, 2018	43,579,557
Net loss			(417,731)		(417,731)
Foreign currency translation adjustment				835,865	835,865
Balance at Mar. 31, 2019	$ 43,580	23,590,204	(5,688,089)	12,671,214	30,616,909
Balance, shares at Mar. 31, 2019	43,579,557
Net loss			(838,103)		(838,103)
Foreign currency translation adjustment				(811,164)	(811,164)
Balance at Jun. 30, 2019	$ 43,580	23,590,204	(6,526,192)	11,860,050	28,967,642
Balance, shares at Jun. 30, 2019	43,579,557
Net loss			(700,954)		(700,954)
Foreign currency translation adjustment				(909,889)	(909,889)
Balance at Sep. 30, 2019	$ 43,580	$ 23,590,204	$ (7,227,146)	$ 10,950,161	$ 27,356,799
Balance, shares at Sep. 30, 2019	43,579,557

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (1,956,788)	$ (3,158,048)
Depreciation and amortization	2,261,800	2,499,114
Bad debt expense	54,708	1,481,786
Deferred income taxes		69,614
Inventory write off	87,542
Changes in assets and liabilities:
Trade accounts and other receivables	(407,733)	(514,428)
Advances to suppliers	(2,980)	106,981
Inventory	1,436,878	471,995
Trade accounts payable	130,642	(516,263)
Accrued taxes payable	23,321	(114,432)
Other payables and accrued expenses	(201,831)	580,689
Advances from customers	(12,670)	86,675
Prepaid expenses	(9,211)	14,005
Net Cash Provided by Operating Activities	1,403,678	1,007,688
Cash Flows from Investing Activities:
Purchases of property and equipment	(85,739)	(33,332)
Net Cash Used in Investing Activities	(85,739)	(33,332)
Cash Flows from Financing Activities:
Payments of construction term loan	(2,188,463)	(2,303,410)
Loan from related party	674,405
Repayments to related party	(209,726)
Net Cash Used in Financing Activities	(1,723,784)	(2,303,410)
Effect of Exchange Rate Changes on Cash	(19,136)	(33,531)
Net (Decrease) Increase in Cash and Cash Equivalents	(424,981)	(1,362,585)
Cash and Cash Equivalents at Beginning of Period	1,186,587	2,030,214
Cash and Cash Equivalents at End of Period	761,606	667,629
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	241,465	351,206
Supplemental Noncash Investing and Financing Activities:
Issuance of banker's acceptances	2,641	847,527
Accounts receivable collected with banker's acceptances	532,537	462,642
Inventory purchased with banker's acceptances	553,183	502,473
Right-of-use assets obtained in exchange for operating lease obligations	$ 231,130

Organization and Significant Ac

Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Liquidity and Going Concern As of September 30, 2019, the Company had cash and cash equivalents of $0.8 million and an accumulated deficit of $7.2 million. During the nine months ended September 30, 2019, the Company's Chairperson, Chief Executive Officer and Interim Chief Financial Officer advanced an aggregate of $722,405, including $674,405 in July, 2019, to provide working capital and enable the Company's required payment of $2.0 million related to its construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, costs for its pipeline products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans to enhance the sales model of prepayment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company's existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have been finalized at the time of filing this Quarterly Report on Form 10-Q and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Organization and Nature of Operations – On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada, pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012. The reincorporation merger was approved by stockholders holding the majority of the Company's outstanding shares of common stock on December 21, 2012. On June 30, 2019, Catalogue of Encouraging Foreign Investment Industries (2019 Edition) (the "2019 Encouraged Catalogue") and Special Administrative Measures for Foreign Investment Access (Negative List) (2019 Edition) (the "2019 Negative List") were jointly released by China's Ministry of Commerce and the National Development and Reform Commission and became effective on July 30, 2019. Industries listed in the 2019 Encouraged Catalogue are the encouraged industries. On the other hand, industries listed in the 2019 Negative List are subject to special management measures. Establishment of wholly foreign-owned enterprises is generally allowed in industries outside of the 2019 Negative List. Foreign investors are not allowed to invest in industries that are expressly prohibited in the 2019 Negative List. The industries that are not expressly prohibited in the Negative List are subject to government approvals and certain special requirements. The majority of pharmaceutical manufacturing industry including the segments under which the Company conducts its business is not included in the 2019 Negative List. Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson's business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines. Consolidation and Basis of Presentation Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. Accounting Estimates Cash and Cash Equivalents Restricted Cash Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 against the allowance for the three and nine months ended September 30, 2019 and 2018, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts. Advances to Suppliers and Advances from Customers Inventory – Valuation of Long-Lived Assets Property, Plant and Equipment Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the buyer picks up the goods at the Company's warehouse. For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. Cost of Revenues Research and Development Basic and Diluted Loss per Common Share There were no potentially dilutive common shares outstanding during the three and nine months ended September 30, 2019 and 2018, respectively. Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy. Interest Rate Risk Recent Accounting Pronouncements Recently Implemented Pronouncements In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases As permitted by the transition guidance of ASU No. 2016-02, the Company adopted the standard by applying the modified retrospective method without the restatement of comparative periods. The Company elected the package of practical expedients, which permits a lessee to not reassess under the new standard its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did not elect the practical expedient which permits the use of hindsight when determining the lease term and assessing right-of-use assets for impairment. As permitted by the transition guidance, the Company used the remaining lease term as of the date of adoption of this standard to estimate discount rates. As permitted by this standard, the Company elected, for all asset classes, the short-term lease exemption. A short-term lease is a lease that, at the commencement date, has a term of twelve months or less and does not include an option to purchase the underlying asset. See Note 9 for additional information on the Company's leases. Accounting Policy for Leases – The discount rate used to measure a lease obligation should be the rate implicit in the lease; however, the Company's operating leases generally do not provide an implicit rate. Accordingly, the Company uses its incremental borrowing rate at lease commencement to determine the present value of lease payments. The incremental borrowing rate is an entity-specific rate which represents the rate of interest a lessee would pay to borrow on a collateralized basis over a similar term with similar payments. Recently Issued Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its condensed consolidated financial statements upon adoption.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: September 30, December 31, 2019 2018 Raw materials $ 2,280,108 $ 3,148,990 Work in process 382,900 493,768 Finished goods 1,310,365 1,412,217 Total Inventory $ 3,973,373 $ 5,054,975

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: September 30, December 31, 2019 2018 Permit of land use $ 398,235 $ 409,612 Building 9,247,632 9,511,832 Plant, machinery and equipment 25,909,977 26,576,409 Motor vehicle 304,118 312,807 Office equipment 204,115 198,292 Total 36,064,077 37,008,952 Less: accumulated depreciation (19,366,821 ) (17,714,573 ) Property, Plant and Equipment, net $ 16,697,256 $ 19,294,379 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $677,395 and $942,555 for the three months ended September 30, 2019 and 2018, respectively and $2,212,731 and $2,405,396 for the nine months ended September 30, 2019 and 2018, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration ("CFDA"). The Company did not obtain CFDA production approval for any medical formulas during the nine months ended September 30, 2019 and 2018 and no costs were reclassified from advances to intangible assets during the nine months ended September 30, 2019 and 2018, respectively. Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $8,536 and $26,861 for the three months ended September 30, 2019 and 2018, respectively, and $49,070 and $93,718 for the nine months ended September 30, 2019, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and also at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the nine months ended September 30, 2019 and 2018. Intangible assets consisted solely of CFDA approved medical formulas as follows: September 30, December 31, 2019 2018 Gross carrying amount $ 4,772,957 $ 4,909,318 Accumulated amortization (4,561,466 ) (4,642,875 ) Net carrying amount $ 211,491 $ 266,443

Advances for Purchases of Intan

Advances for Purchases of Intangible Assets	9 Months Ended
	Sep. 30, 2019
Advances for Purchases of Intangible Assets [Abstract]
ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS	NOTE 5 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS In order to expand the number of medicines the Company manufactured and marketed, it entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts was for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company holds the title to one valid patent that is related to one of its medical formulas. With respect to the other patent title the Company held, the management decided not to renew the patent during 2019 as it did not have any practical value because the related advance purchase to this pipeline product was written off as of December 31, 2018. Prior to entering into contracts with the Company, laboratories are typically required to complete all research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA. In order to promote the standard of the pharmaceutical industry in China in line with international standards, significant changes have taken place in the policies and regulations in this industry in recent years. A series of policies on consistency evaluation and drug review process have been issued, and more potential reforms and adjustments are underway. In this context, the Company believes that the uncertainties in the timetables for obtaining CFDA production approvals for products under research are increasing. Under the new regulations and policy environment, the criteria for formulations' development are more stringent. The Company must supplement and improve the corresponding processes and standards to meet the latest requirements of CFDA in accordance with the requirements of consistency evaluation. As a result, the Company anticipates an extended timeline on the approval process of its current pipeline products. Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets. To date, no formula has failed to receive CFDA production approval nor has the Company been informed or been made aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval, and if the Company does not receive such approval, it will enforce its contractual rights to receive a refund from the laboratory or have the payments applied to another medical formula with the same laboratory. As of September 30, 2019, the Company was obligated to pay laboratories and others approximately $0.3 million upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company's board of directors ("Board") had previously advanced the Company an aggregate amount of $1,354,567 as of September 30, 2019 and December 31, 2018 which are recorded as "Other payables – related parties" on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expenses for each of the three months ended September 30, 2019 and 2018 were $3,386 and $3,386, respectively. Total interest expenses for the nine months ended September 30, 2019 and 2018 were $10,159 and $10,159, respectively. The Company received advances totaling $722,405 and $278,696 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. These amounts are recorded as "Other payables – related parties" on the accompanying condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018, respectively. An aggregate of $230,696 was repaid during the nine months ended September 30, 2019. On July 8, 2019 the Company entered into a loan agreement to borrow cash of RMB 4,770,000 ($674,405) from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. Total interest expense related to the loan for the three and nine months ended September 30, 2019 were both $3,896. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in "Other payables" in the accompanying condensed consolidated balance sheets totaling $2,063,186 and $2,051,186 as of September 30, 2019 and December 31, 2018, respectively.

Banker's Acceptance Notes Payab

Banker's Acceptance Notes Payable	9 Months Ended
	Sep. 30, 2019
Banking and Thrift [Abstract]
BANKER'S ACCEPTANCE NOTES PAYABLE	NOTE 7 – BANKER'S ACCEPTANCE NOTES PAYABLE In April 2016, the Company entered into a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the banker's acceptance notes issued to the third parties. The amount of these deposited balances is shown as "Restricted cash" on the accompanying condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the banker's acceptance notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. As of September 30, 2019 and December 31, 2018, the Company had outstanding banker's acceptance notes in the amount of $489,208 and $1,273,940, respectively.

Construction Loan Facility

Construction Loan Facility	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
CONSTRUCTION LOAN FACILITY	NOTE 8 – CONSTRUCTION LOAN FACILITY The Company obtained a construction loan facility, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company's new production facility and the included production line equipment and machinery. The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2016, 2017 and 2018 the interest rate was adjusted to 5.39%, 5.39% and 5.39%, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment due within six month period after July 10, 2015 and the second annual payment due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required payments due under the loan. As of September 30, 2019, the Company had no additional amounts available to it under this facility. During the nine months ended September 30, 2019, the Company made principal payments in the amount of $2,188,463 (RMB15,000,000). All required payments have been made pursuant to the terms of the loan. Principal payments required for the remaining term of the loan facility as of September 30, 2019 are as follows: Year Amount 2019 - 2020 2,120,771 2021 2,120,771 $ 4,241,542 Fair Value of Construction Loan Facility

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's incremental borrowing rate at the initial measurement date. For the three and nine months ended September 30, 2019, operating lease cost was $20,349 and $66,804, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $21,629 and $71,005, respectively. As of September 30, 2019, the Company reported operating lease right of use assets and operating lease liabilities of $157,177 and $159,948, respectively. As of September 30, 2019, its operating leases had a weighted average remaining lease term of 1.77 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month periods ended September 30: 2020 $ 94,672 2021 72,390 Total undiscounted cash flows 167,062 Less: Imputed interest (7,114 ) 159,948 Less: Operating lease liabilities, current portion (88,996 ) Operating lease liabilities, net of current portion $ 70,952 The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interests and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2018, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2015 through December 31, 2018 and the Chinese income tax return for the year ended December 31, 2018 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. The provision for income taxes consisted of the following: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Current $ - $ - $ - $ - Deferred - 160,485 - 111,910 Total income tax expense $ - $ 160,485 $ - $ 111,910 As of September 30, 2019, the Company had net operating loss carryforwards for PRC tax purposes of approximately $52.6 million which are available to offset any future taxable income through 2024. Approximately $3.8 million of these carryforwards will expire in December 2019. The Company also has net operating losses for United States federal income tax purposes of approximately $5.9 million of which $5.1 million which are available to offset future taxable income, if any, through 2038, and $0.6 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. Recent U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of September 30, 2019 and December 31, 2018. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $26,735,211 and $26,990,951 as of September 30, 2019 and December 31, 2018, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker's acceptance notes it holds at December 31, 2018. The banker's acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at December 31, Reporting Date Using Description 2018 Level 1 Level 2 Level 3 Banker's acceptance notes $ 20,579 $ - $ 20,579 $ - Total $ 20,579 $ - $ 20,579 $ -

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS' EQUITY The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company's Board. Employee Stock Options 2010 Incentive Plan On November 12, 2010, the Company's Board adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through September 30, 2019, there were 175,000 shares of restricted stock granted and outstanding under the Plan. No options were outstanding as of September 30, 2019 under the Plan. There were no securities issued from the Plan during each of the nine months ended September 30, 2019 and 2018. The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three and nine months ended September 30, 2019 and 2018. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company's common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. As of September 30, 2019, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Economic environment - In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2019
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 14 – CONCENTRATIONS For the nine months ended September 30, 2019, no customer accounted for more than 10% of sales and two customers accounted for 49.5% and 10.7% of accounts receivable. Two suppliers accounted for 21.7% and 19.3% of the Company's raw material purchases. For the nine months ended September 30, 2018, no customer accounted for more than 10% of sales and two customers accounted for 47.3% and 14.0% of accounts receivable. Three suppliers accounted for 23.6%, 20.5% and 13.5% of raw material purchases.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS In accordance with ASC 855-10 the Company's operations were reviewed by management subsequent to September 30, 2019 to the date these condensed consolidated financial statements were issued, and have determined the Company not have any material subsequent events to disclose in these condensed consolidated financial statements.

Organization and Significant _2

Organization and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada, pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012. The reincorporation merger was approved by stockholders holding the majority of the Company's outstanding shares of common stock on December 21, 2012. On June 30, 2019, Catalogue of Encouraging Foreign Investment Industries (2019 Edition) (the "2019 Encouraged Catalogue") and Special Administrative Measures for Foreign Investment Access (Negative List) (2019 Edition) (the "2019 Negative List") were jointly released by China's Ministry of Commerce and the National Development and Reform Commission and became effective on July 30, 2019. Industries listed in the 2019 Encouraged Catalogue are the encouraged industries. On the other hand, industries listed in the 2019 Negative List are subject to special management measures. Establishment of wholly foreign-owned enterprises is generally allowed in industries outside of the 2019 Negative List. Foreign investors are not allowed to invest in industries that are expressly prohibited in the 2019 Negative List. The industries that are not expressly prohibited in the Negative List are subject to government approvals and certain special requirements. The majority of pharmaceutical manufacturing industry including the segments under which the Company conducts its business is not included in the 2019 Negative List. Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson's business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.
Accounting Estimates	Accounting Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Restricted Cash	Restricted Cash
Trade Accounts Receivable and Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 against the allowance for the three and nine months ended September 30, 2019 and 2018, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.
Advances to Suppliers and Advances from Customers	Advances to Suppliers and Advances from Customers
Inventory	Inventory –
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets
Property, Plant and Equipment	Property, Plant and Equipment
Revenue Recognition	Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon buyer's designated carrier or the buyer picks up the goods at the Company's warehouse. For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules.
Cost of Revenues	Cost of Revenues
Research and Development	Research and Development
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share There were no potentially dilutive common shares outstanding during the three and nine months ended September 30, 2019 and 2018, respectively.
Credit Risk	Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.
Interest Rate Risk	Interest Rate Risk
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Implemented Pronouncements In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases As permitted by the transition guidance of ASU No. 2016-02, the Company adopted the standard by applying the modified retrospective method without the restatement of comparative periods. The Company elected the package of practical expedients, which permits a lessee to not reassess under the new standard its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did not elect the practical expedient which permits the use of hindsight when determining the lease term and assessing right-of-use assets for impairment. As permitted by the transition guidance, the Company used the remaining lease term as of the date of adoption of this standard to estimate discount rates. As permitted by this standard, the Company elected, for all asset classes, the short-term lease exemption. A short-term lease is a lease that, at the commencement date, has a term of twelve months or less and does not include an option to purchase the underlying asset. See Note 9 for additional information on the Company's leases.
Accounting Policy for Leases	Accounting Policy for Leases – The discount rate used to measure a lease obligation should be the rate implicit in the lease; however, the Company's operating leases generally do not provide an implicit rate. Accordingly, the Company uses its incremental borrowing rate at lease commencement to determine the present value of lease payments. The incremental borrowing rate is an entity-specific rate which represents the rate of interest a lessee would pay to borrow on a collateralized basis over a similar term with similar payments. Recently Issued Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its condensed consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of inventory	September 30, December 31, 2019 2018 Raw materials $ 2,280,108 $ 3,148,990 Work in process 382,900 493,768 Finished goods 1,310,365 1,412,217 Total Inventory $ 3,973,373 $ 5,054,975

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	September 30, December 31, 2019 2018 Permit of land use $ 398,235 $ 409,612 Building 9,247,632 9,511,832 Plant, machinery and equipment 25,909,977 26,576,409 Motor vehicle 304,118 312,807 Office equipment 204,115 198,292 Total 36,064,077 37,008,952 Less: accumulated depreciation (19,366,821 ) (17,714,573 ) Property, Plant and Equipment, net $ 16,697,256 $ 19,294,379
Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets	Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	September 30, December 31, 2019 2018 Gross carrying amount $ 4,772,957 $ 4,909,318 Accumulated amortization (4,561,466 ) (4,642,875 ) Net carrying amount $ 211,491 $ 266,443

Construction Loan Facility (Tab

Construction Loan Facility (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of principal payments	Year Amount 2019 - 2020 2,120,771 2021 2,120,771 $ 4,241,542

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of minimum lease payments for the company's operating leases liabilities	2020 $ 94,672 2021 72,390 Total undiscounted cash flows 167,062 Less: Imputed interest (7,114 ) 159,948 Less: Operating lease liabilities, current portion (88,996 ) Operating lease liabilities, net of current portion $ 70,952

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	Three Months Ended Nine Months Ended 2019 2018 2019 2018 Current $ - $ - $ - $ - Deferred - 160,485 - 111,910 Total income tax expense $ - $ 160,485 $ - $ 111,910

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value	Fair Value Measurements at December 31, Reporting Date Using Description 2018 Level 1 Level 2 Level 3 Banker's acceptance notes $ 20,579 $ - $ 20,579 $ - Total $ 20,579 $ - $ 20,579 $ -

Organization and Significant _3

Organization and Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jul. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	May 25, 2005
Organization and Significant Accounting Policies (Textual)
Bad debt expense	$ 31,304	$ 1,129,105	$ 54,708	$ 1,481,786
Trade accounts receivable	0	0	0	0
Operating lease right of use assets	157,177		157,177
Operating lease liabilities	159,948		159,948
Cash and cash equivalents	761,606	$ 667,629	761,606	$ 667,629		1,186,587	$ 2,030,214
Accumulated deficit	(7,227,146)		(7,227,146)			(5,270,358)
Other payables - related parties aggregate amount	1,354,567		1,354,567			1,354,567
Accounting Standards Update 2016-02 [Member]
Organization and Significant Accounting Policies (Textual)
Operating lease right of use assets						236,055
Operating lease liabilities						236,055
Management [Member]
Organization and Significant Accounting Policies (Textual)
Advance amount provided working capital purpose					$ 674,405
Construction loan facility					$ 2,000,000
Other payables - related parties aggregate amount	$ 722,405		$ 722,405			$ 278,696
British Virgin Islands corporation [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage	100.00%		100.00%
Nevada corporation [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage	100.00%		100.00%
Onny [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage								100.00%

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 2,280,108	$ 3,148,990
Work in process	382,900	493,768
Finished goods	1,310,365	1,412,217
Total Inventory	$ 3,973,373	$ 5,054,975

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Permit of land use	$ 398,235	$ 409,612
Building	9,247,632	9,511,832
Plant, machinery and equipment	25,909,977	26,576,409
Motor vehicle	304,118	312,807
Office equipment	204,115	198,292
Total	36,064,077	37,008,952
Less: accumulated depreciation	(19,366,821)	(17,714,573)
Property, Plant and Equipment, net	$ 16,697,256	$ 19,294,379

Property, Plant and Equipment_3

Property, Plant and Equipment (Details 1)	9 Months Ended
	Sep. 30, 2019
Minimum [Member] | Permit of land use [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years
Minimum [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	20 years
Minimum [Member] | Plant, machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Motor vehicle [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Office equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum [Member] | Permit of land use [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	70 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	49 years
Maximum [Member] | Plant, machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Motor vehicle [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Office equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

Property, Plant and Equipment_4

Property, Plant and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment (Textual)
Depreciation expense	$ 677,395	$ 942,555	$ 2,212,731	$ 2,405,396

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Intangible assets consisted solely of CFDA approved medical formulas as follows:
Gross carrying amount	$ 4,772,957	$ 4,909,318
Accumulated amortization	(4,561,466)	(4,642,875)
Net carrying amount	$ 211,491	$ 266,443

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Intangible Assets (Textual)
Amortization expense relating to intangible assets	$ 8,536	$ 26,861	$ 49,070	$ 93,718

Advances for Purchases of Int_2

Advances for Purchases of Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Advances for Purchases of Intangible Assets (Textual)
Laboratories and others	$ 300,000

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Jul. 08, 2019USD ($)	Jul. 08, 2019CNY (¥)	Dec. 31, 2018USD ($)
Related Party Transactions (Textual)
Interest rate	1.00%		1.00%		4.35%	4.35%
Interest expenses	$ 3,386	$ 3,386	$ 10,159	$ 10,159
Other payables - related parties aggregate amount	1,354,567		1,354,567				$ 1,354,567
Other payables	2,063,186		2,063,186				2,051,186
Loan agreement to borrow					$ 674,405
Management [Member]
Related Party Transactions (Textual)
Interest expenses			3,896
Other payables - related parties aggregate amount	722,405		722,405				$ 278,696
Aggregate compensation payable	$ 230,696		$ 230,696
Management [Member] | RMB [Member]
Related Party Transactions (Textual)
Loan agreement to borrow | ¥						¥ 4,770,000

Banker's Acceptance Notes Pay_2

Banker's Acceptance Notes Payable (Details)	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019CNY (¥)	Dec. 31, 2018USD ($)
Banker's Acceptance Notes Payable (Textual)
Maximum amount of agreement	$ 4,500,000
Agreement payments fees, description	In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank.
Banker's acceptance notes payable outstanding	$ 489,208		$ 1,273,940
RMB [Member]
Banker's Acceptance Notes Payable (Textual)
Maximum amount of agreement | ¥		¥ 30,000,000

Construction Loan Facility (Det

Construction Loan Facility (Details)	Sep. 30, 2019USD ($)
Debt Disclosure [Abstract]
2019
2020	2,120,771
2021	2,120,771
Total	$ 4,241,542

Construction Loan Facility (D_2

Construction Loan Facility (Details Textual)	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019CNY (¥)	Jun. 21, 2013USD ($)	Jun. 21, 2013CNY (¥)
Construction Loan Facility (Textual)
Construction loan amount | $			$ 13,000,000
Description of loan interest rates	The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. The loan bears interest based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2016, 2017 and 2018 the interest rate was adjusted to 5.39%, 5.39% and 5.39%, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment due within six month period after July 10, 2015 and the second annual payment due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015.
Principal amount | $	$ 2,188,463
RMB [Member]
Construction Loan Facility (Textual)
Construction loan amount | ¥				¥ 80,000,000
Principal amount | ¥		¥ 15,000,000

Leases (Details)

Leases (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
2020	$ 94,672
2021	72,390
Total undiscounted cash flows	167,062
Less: Imputed interest	(7,114)
Total lease liability	159,948
Less: Operating lease liabilities, current portion	(88,996)
Operating lease liabilities, net of current portion	$ 70,952

Leases (Details Textual)

Leases (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Leases (Textual)
Operating leases cost	$ 20,349	$ 66,804
Cash Paid for operating leases	21,629	71,005
Operating leases right of use assets	157,177	157,177
Operating leases liabilities	$ 159,948	$ 159,948
Weighted average remaining lease term	1 year 9 months 7 days	1 year 9 months 7 days
Weighted average discount rate	4.75%	4.75%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Current
Deferred		160,485		111,910
Total income tax expense		$ 160,485		$ 111,910

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Income Taxes (Textual)
Net operating loss carryforwards for PRC tax	$ 52,600,000
Valuation allowance for deferred tax assets	$ 26,735,211	$ 26,990,951
Enterprise income tax rate	25.00%
Net operating loss expiration, description	The Company had net operating loss carryforwards for PRC tax purposes of approximately $52.6 million which are available to offset any future taxable income through 2024. Approximately $3.8 million of these carryforwards will expire in December 2019. The Company also has net operating losses for United States federal income tax purposes of approximately $5.9 million of which $5.1 million which are available to offset future taxable income, if any, through 2038, and $0.6 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
Description of federal corporate income tax rate	The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.

Fair Value Measurements (Detail

Fair Value Measurements (Details)	Dec. 31, 2018USD ($)
Banker's acceptance notes	$ 20,579
Total	20,579
Fair Value, Inputs, Level 1 [Member]
Banker's acceptance notes
Total
Fair Value, Inputs, Level 2 [Member]
Banker's acceptance notes	20,579
Total	20,579
Fair Value, Inputs, Level 3 [Member]
Banker's acceptance notes
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Stockholders' Equity (Textual)
Common stock, shares authorized	95,000,000	95,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
2010 Incentive Plan [Member]
Stockholders' Equity (Textual)
Common stock issued for equity awards	4,000,000
Restricted stock granted and outstanding	175,000

Concentrations (Details)

Concentrations (Details)	9 Months Ended
	Sep. 30, 2019CustomerSuppliers / Number	Sep. 30, 2018CustomerSuppliers / Number
Sales Revenue, Net [Member]
Concentrations (Textual)
Concentrations risk, percentage	10.00%	10.00%
Accounts Receivable [Member]
Concentrations (Textual)
Number of customers | Customer	2	2
Accounts Receivable [Member] | Customer One [Member]
Concentrations (Textual)
Concentrations risk, percentage	49.50%	47.30%
Accounts Receivable [Member] | Customer Two [Member]
Concentrations (Textual)
Concentrations risk, percentage	10.70%	14.00%
Raw Material Purchases [Member]
Concentrations (Textual)
Number of suppliers | Suppliers / Number	2	3
Raw Material Purchases [Member] | Supplier One [Member]
Concentrations (Textual)
Concentrations risk, percentage	21.70%	23.60%
Raw Material Purchases [Member] | Supplier Two [Member]
Concentrations (Textual)
Concentrations risk, percentage	19.30%	20.50%
Raw Material Purchases [Member] | Supplier Three [Member]
Concentrations (Textual)
Concentrations risk, percentage		13.50%